Hematopoietic stem cell transplantation with reduced toxicity conditioning regimen in mitochondrial neurogastrointestinal encephalopathy syndrome
Pediatric Blood & Cancer · 2023-07 · 70 (7)
DOI: 10.1002/pbc.30334 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 12.04.2023. Verfasst von Gülcihan Ozek und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Pediatric Hemathology and Oncology, Ege University Medical Faculty, Izmir, Turkey. Hauptthemen laut MEDLINE: Graft vs Host Disease, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Medical Research Council.
Abstract (Originalsprache)
Background
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a rare autosomal recessive disorder due to mutations in the TYMP gene. Clinical findings are characterized by neurologic manifestations and severe gastrointestinal dysfunction. The syndrome is usually fatal, the most effective treatment appears to be hematopoietic stem cell transplantation (HSCT). Procedure In this retrospective study, we evaluated HSCT that was performed using a reduced toxicity myeloablative conditioning regimen in patients with MNGIE at our center.
Results
A total of six allogeneic transplant procedures were performed in four patients. Three patients had fully matched donors, and one patient had a haploidentical donor. Treosulfan‐based myeloablative conditioning regimen was applied in five of six transplants. Bone marrow was used as a stem cell source. One patient is being followed up in the 4th year of posttransplant with full chimeric and without graft versus host disease (GVHD). One patient died of acute stage IV gastrointestinal system GVHD. Two patients underwent second transplantation due to engraftment failure, one of which was the patient who had a haploidentical transplant.
Conclusions
Treosulfan‐based regimen is well tolerated, although engraftment failure with this conditioning regimen can be a significant problem. We share our haploidentical transplant experience, which will be the first reported case in the literature.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Pediatric Hemathology and Oncology, Ege University Medical Faculty, Izmir, Turkey.
- Department of Pediatrics, Division of Metabolism and Nutrition, Ege University Medical Faculty, Izmir, Turkey.
- Department of Cell Biology, Institute of Molecular and Clinical Sciences, St George's University of London, London, UK.
- Department of Pediatrics, Division of Metabolism and Nutrition, Çukurova University Medical Faculty, Adana, Turkey.
ORCID-Profile: Gülcihan Ozek, Yeşim Oymak
Förderung
- Medical Research Council
Zitieren
APA
Ozek, G., Aksoylar, S., Uçar, S. K., Canda, E., Akcan, M., Cartı, O., Siviş, Z. O., Oymak, Y., Yazıcı, H., Bax, B., Bulut, F. D., Yoldaş Çelik, M., Erdem, F., Çoker, M., & Kansoy, S. (2023). Hematopoietic stem cell transplantation with reduced toxicity conditioning regimen in mitochondrial neurogastrointestinal encephalopathy syndrome. Pediatric Blood & Cancer, 70(7). https://doi.org/10.1002/pbc.30334
Vancouver
Ozek G, Aksoylar S, Uçar SK, Canda E, Akcan M, Cartı O, et al. Hematopoietic stem cell transplantation with reduced toxicity conditioning regimen in mitochondrial neurogastrointestinal encephalopathy syndrome. Pediatric Blood & Cancer. 2023;70(7). doi:10.1002/pbc.30334
BibTeX
@article{Ozek2023,
author = {Ozek, Gülcihan and Aksoylar, Serap and Uçar, Sema Kalkan and Canda, Ebru and Akcan, Mediha and Cartı, Ozgür and Siviş, Zuhal Onder and Oymak, Yeşim and Yazıcı, Havva and Bax, Bridget and Bulut, Fatma Derya and Yoldaş Çelik, Merve and Erdem, Fehime and Çoker, Mahmut and Kansoy, Savaş},
title = {Hematopoietic stem cell transplantation with reduced toxicity conditioning regimen in mitochondrial neurogastrointestinal encephalopathy syndrome},
journal = {Pediatric Blood & Cancer},
year = {2023},
volume = {70},
number = {7},
doi = {10.1002/pbc.30334}
}
EUVIMED